Home / Pharmaceuticals / Short Bowel Syndrome Market By Drug Type (GLP-2, Glutamine, Growth Hormones, Other Drugs) - Growth, Future Prospects, And Competitive Analysis, 2015 -2025

Short Bowel Syndrome Market By Drug Type (GLP-2, Glutamine, Growth Hormones, Other Drugs) - Growth, Future Prospects, And Competitive Analysis, 2015 -2025

Published: Jul 2017 | Report Code: 58584-07-17

Short bowel syndrome is a group of complex diseases that occurs due to malfunction of a portion of small and/or large intestine. The individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other vital elements which leads to malnutrition, weight loss.

The report titled “Global Short Bowel Syndrome Market- Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into Short Bowel Syndrome market along with the market size and estimates for the duration 2017 to 2025. The research study covers in-depth analysis of market segments based on drug type, and different geographical region.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global Short Bowel Syndrome market, attractive investment proposition and market positioning of key manufacturers sections.

Geographically, the global Short Bowel Syndrome market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as pipeline analysis, market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global Short Bowel Syndrome market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global Short Bowel Syndrome market. This report concludes with company profiles section that highlights major information about the key players engaged in global Short Bowel Syndrome market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report. 

Thus, the research study provides a holistic view of the global Short Bowel Syndrome market, offering market size and estimates for the period from 2017 to 2025, keeping in mind the above-mentioned factors.

Short Bowel Syndrome Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Short Bowel Syndrome Market Portraiture
2.2 Short Bowel Syndrome Market, by Drug Type, 2016 (US$ Mn)
2.3 Short Bowel Syndrome Market, by Geography, 2016 (Value %)

Chapter 3 Global Short Bowel Syndrome Market Analysis
3.1 Global Short Bowel Syndrome Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Analysis: Global Short Bowel Syndrome Market, 2016 (Value %)

Chapter 4 Global Short Bowel Syndrome Market Analysis, By Drug Type
4.1 Overview
4.1.1 Market Attractive Proposition of Short Bowel Syndrome Market, by Drug Type, 2016
4.2 GLP-2
4.3 Glutamine
4.4 Growth Hormones
4.5 Other Drugs

Chapter 5 Global Short Bowel Syndrome Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Short Bowel Syndrome Market, by Drug Type, 2015-2025 (US$ Mn)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Short Bowel Syndrome Market, by Drug Type, 2015-2025 (US$ Mn)
5.4 Asia-Pacific (China, Japan & Rest of Asia-Pacific)
5.4.1 Asia Pacific Short Bowel Syndrome Market, by Drug Type, 2015-2025 (US$ Mn)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Short Bowel Syndrome Market, by Drug Type, 2015-2025 (US$ Mn)
5.6 Middle East and Africa
5.6.1 Middle East and Africa Short Bowel Syndrome Market, by Drug Type, 2015-2025 (US$ Mn)

Chapter 6 Company Profiles
6.1 Ardelyx, Inc.
6.2 Emmaus Life Sciences, Inc.
6.3 GLyPharma Therapeutic, Inc.
6.4 Merck KGaA
6.5 Naia Pharmaceuticals, Inc.
6.6 Nutrinia Ltd.
6.7 OxThera
6.8 Sancilio & Company, Inc.
6.9 Shire plc
6.10 Zealand Pharma A/S

List Of Table : 

TABLE 1 Global Short Bowel Syndrome Market, By Drug Type (US$ Mn), 2015– 2025 (Value)
TABLE 2 Global Short Bowel Syndrome Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 3 North America Short Bowel Syndrome Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 4 North America Short Bowel Syndrome Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Short Bowel Syndrome Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Short Bowel Syndrome Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Asia Pacific Short Bowel Syndrome Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 8 Asia - Pacific Short Bowel Syndrome Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Latin America Short Bowel Syndrome Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Short Bowel Syndrome Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Middle East and Africa Short Bowel Syndrome Market, by Drug Type, 2015 – 2025 (US$
Mn)
TABLE 13 Ardelyx, Inc.: Company Snapshot (Business Description; Financial Performance; Product
Position/Portfolio; News Coverage)
TABLE 14 Emmaus Life Sciences, Inc.: Company Snapshot (Business Description; Financial
Performance; Product Position/Portfolio; News Coverage)
TABLE 15 GLyPharma Therapeutic, Inc.: Company Snapshot (Business Description; Financial
Performance; Product Position/Portfolio; News Coverage)
TABLE 16 Merck KGaA: Company Snapshot (Business Description; Financial Performance; Product
Position/Portfolio; News Coverage)
TABLE 17 Naia Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial
Performance; Product Position/Portfolio; News Coverage)
TABLE 18 Nutrinia Ltd.: Company Snapshot (Business Description; Financial Performance; Product
Position/Portfolio; News Coverage)
TABLE 19 OxThera: Company Snapshot (Business Description; Financial Performance; Product
Position/Portfolio; News Coverage)
TABLE 20 Sancilio & Company, Inc.: Company Snapshot (Business Description; Financial
Performance; Product Position/Portfolio; News Coverage)
TABLE 21 Shire plc: Company Snapshot (Business Description; Financial Performance; Product
Position/Portfolio; News Coverage)
TABLE 22 Zealand Pharma A/S: Company Snapshot (Business Description; Financial Performance;
Product Position/Portfolio; News Coverage)

List Of Figures :

FIG. 1 Short Bowel Syndrome Market: Research Methodology
FIG. 2 Short Bowel Syndrome Market, by Drug Type, 2016 (US$ Mn)
FIG. 3 Short Bowel Syndrome Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition
FIG. 5 Competitive Analysis: Global Short Bowel Syndrome Market, 2016 (Value %)
FIG. 6 Global GLP-2 Market(US$ Mn), 2015-2025
FIG. 7 Global Glutamine Market(US$ Mn), 2015-2025
FIG. 8 Global Growth Hormones Market (US$ Mn), 2015-2025
FIG. 9 Global Other Drugs Market (US$ Mn), 2015-2025 

Based on the type of Drug, the Nonalcoholic Steatohepatitis market is segmented into:

  • GLP-2
  • Glutamine
  • Growth Hormone
  • Others

Short bowel syndrome is a group of complex diseases that occurs due to malfunction of a portion of small and/or large intestine. The individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other vital elements which leads to malnutrition, weight loss. However, in some cases, short bowel syndrome can lead to severe, disabling and life-threatening complications. There is no particular cure to this disorder however surgical removal (resection) of half or more of the small intestine is effective. Short bowel syndrome can lead to Crohn’s disease, injury or trauma to the small intestine. Such complications are making a significant contribution to the growth of the short bowel syndrome market. On the basis of drug the market is segmented into GLP-2, glutamine, growth hormone and others. GLP-2 currently holds the largest market in terms of drug in the short bowel syndrome market as it is marketed in U.S. and Europe under the brand name Gattex and Revestive in Europe and other international market. The drugs currently holds the orphan drug status, and the exclusivity of the drugs in the treatment of the short bowel syndrome would further draw huge revenue during the forecast period.

Short Bowel Syndrome Market

For the purpose of this study, the global short bowel syndrome market is categorized as follows:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Short Bowel Syndrome Market

For the purpose of this study, the global short bowel syndrome market is segmented into regional markets such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America held the largest market in the short bowel syndrome market with U.S. being the highest grossing country. The major factor driving the U.S. short bowel syndrome market is the rising prescription of Gattex, which is the only approve drug in the U.S. Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. Europe held the second largest market as in the U.S., approximately 6,000-7,000 SBS patients are dependent on parenteral support with a similar prevalence in Europe. Revestive is the highest grossing drug in the Europe which is marketed by Shire, plc. Moreover, efficient reimbursement scenario in North America and Europe would further drive the market for short bowel syndrome during the forecast period.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients